Charles River Laboratories International, Inc., a contract research organization, has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will provide discovery and preclinical development services that will enable BioMotiv to advance discoveries sourced from academic research and non-governmental organizations into medicines.

Charles River has committed to invest up to $10 million in BioMotiv. Through the agreement, Charles River will be the preferred drug discovery and preclinical development partner for BioMotiv's portfolio of technologies and companies. As part of this new relationship, Professor Julie Frearson, Executive Director of Scientific Alliances for Charles River, will be joining BioMotiv's Advisory Board.

Launched in 2012, BioMotiv is the for-profit component of The Harrington Project, a $250 million initiative with an aim of identifying, funding, and advancing the development of medical discoveries from physician-scientists throughout the United States and United Kingdom.

Source: Charles River Laboratories